Drug Shortages Give Ben Venue Relief In FDA Consent Decree

This article was originally published in The Gold Sheet

28 Feb 2013
News

Brenda Sandburg @brendasandburg Brenda.Sandburg@informa.com

Executive Summary

The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS000739

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS000739

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Drug Shortages Give Ben Venue Relief In FDA Consent Decree

News

Executive Summary

Related Content

FDA Drug Shortage Strategy: Enforcement Discretion, Patient Public Relations

GPhA’s New VP-Regulatory Sciences Has Expertise In Generic Injectable Business

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert